HHHisanori Horiuchi

Hisanori Horiuchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hisanori Horiuchi has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Ryutaro Shirakawa

    The Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

    5 shared publications
  • Tomohiro Kimura

    The Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

    3 shared publications
  • Nobuhiro Yaoita

    From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (N.Y., Y.F., K.S., S.M., Y.M., K.N., M.M., S.T., T.A., S.Y., K.S., H.S.); and Department of Molecular and Cellular Biology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan (R.S., T.K., H.H.).

    2 shared publications
  • T Kita

    Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    2 shared publications
  • Takeshi Kimura

    Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University

    2 shared publications
  • Tomoyuki Ikeda

    Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University

    2 shared publications

Latest Publications

  • Open Access

    Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP

    by Kyosuke Shishikura, Takahiro Horiuchi, Natsumi Sakata, Duc‐Anh Trinh, Ryutaro Shirakawa, Tomohiro Kimura, Yujiro Asada, Hisanori Horiuchi

    Background and Purpose: Upon stimulation, neutrophils release their nuclear contents called neutrophil extracellular traps (NETs), which contain unfolded chromatin and lysosomal enzymes. NETs have been demonstrated to play a critical role in host defence, although the role of PGE2, a bioactive substance generated in inflammatory tissues, in the formation of NETs remains unclear.Experimental Approach: The effects of PGE2, agonists and antagonists of its receptors, and modulators of the cAMP–PKA pathway on the formation of NETs were examined in vitro in isolated neutrophils and in vivo in a newly established mouse model.Key Results: PGE2 inhibited PMA‐induced NET formation in vitro through EP2 and EP4 Gαs‐coupled receptors. Incubation with a cell‐permeable cAMP analogue, dibutyryl cAMP, or various inhibitors of a cAMP‐degrading enzyme, PDE, also suppressed NET formation. In the assay established here, where an agarose gel was s.c. implanted in mice and NET formation was detected on the surface of the gel, the extent of the NET formed was inhibited in agarose gels containing rolipram, a PDE4 inhibitor, and butaprost, an EP2 receptor agonist.Conclusions and Implications: PGE2 inhibits NET formation through the production of cAMP. These findings will contribute to the development of novel treatments for NETosis‐related diseases.


  • Platelets Are Highly Activated in Patients of Chronic Thromboembolic Pulmonary Hypertension

    by Nobuhiro Yaoita, Ryutaro Shirakawa, Yoshihiro Fukumoto, Koichiro Sugimura, Satoshi Miyata, Yutaka Miura, Kotaro Nochioka, Masanobu Miura, Shunsuke Tatebe, Tatsuo Aoki, et al.

    Objective—: Chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease that is distinct from pulmonary arterial hypertension (PAH). Although CTEPH is characterized by obstruction of major pulmonary artery because of chronic thrombus, it remains unclear whether CTEPH is associated with prothrombotic condition. Approach and Results—: In addition to conventional markers, GTP-bound levels of Rap1, RhoA, RalA, Rac1, and Ras in platelets, which are implicated for platelet activation, were measured in patients without pulmonary hypertension (non-PH, n=15), patients with PAH (n=19), and patients with CTEPH (n=25). Furthermore, the responsiveness to ex vivo thrombin stimulation was also evaluated. The ratios of the P-selectin positive platelets in the non-PH patients, patients with PAH, and patients with CTEPH were 1.40% (median and interquartile range, 0.83–1.82), 2.40% (1.80–3.39), and 2.63% (1.90–8.22), respectively (non-PH versus CTEPH, P P =0.01). GTP-bound RhoA was 1.79% (0.94–2.83), 4.03% (2.01–5.14), and 2.01% (1.22–2.48), respectively (non-PH versus PAH, P =0.04), and GTP-bound RalA was 1.58% (1.08–2.11), 3.02% (2.03–3.54), and 2.64% (1.42–4.28), respectively (non-PH versus PAH, P =0.023; non-PH versus CTEPH, P =0.048). In contrast, Rac1, Rap1, or Ras was not activated in any groups. The platelets of patients with CTEPH exhibited hyperresponsiveness to ex vivo thrombin stimulation compared with those of non-PH patients when evaluated for the surface markers. Either D-dimer or fibrin degradation product level was not increased in patients with CTEPH. Conclusions—: These results provide the first direct evidence that platelets of patients with CTEPH are highly activated and exhibit hyperresponsiveness to thrombin stimulation.


  • The antimalarial drugs chloroquine and primaquine inhibit pyridoxal kinase, an essential enzyme for vitamin B6 production

    by Tomohiro Kimura, Ryutaro Shirakawa, Nobuhiro Yaoita, Takashi Hayashi, Keisuke Nagano, Hisanori Horiuchi

    Quinoline derivatives such as chloroquine and primaquine are widely used for the treatment of malaria. These drugs are also used for the treatment of trypanosomiasis, and more recently for cancer therapy. However, molecular target(s) of these drugs remain unclear. In this study, we have identified human pyridoxal kinase as a binding protein of primaquine. Primaquine inhibited pyridoxal kinases of malaria, trypanosome and human, while chloroquine inhibited only malaria pyridoxal kinase. Thus, we have identified pyridoxal kinase as a possible target molecule of the antimalarial drugs chloroquine and primaquine.


  • Open Access

    Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer

    by R Saito, R Shirakawa, H Nishiyama, T Kobayashi, M Kawato, T Kanno, K Nishizawa, Y Matsui, T Ohbayashi, M Horiguchi, et al.

    The small GTPase Ral is known to be highly activated in several human cancers, such as bladder, colon and pancreas cancers. It is reported that activated Ral is involved in cell proliferation, migration and metastasis of bladder cancer. This protein is activated by Ral guanine nucleotide exchange factors (RalGEFs) and inactivated by Ral GTPase-activating proteins (RalGAPs), the latter of which consist of heterodimers containing a catalytic α1 or α2 subunit and a common β subunit. In Ras-driven cancers, such as pancreas and colon cancers, constitutively active Ras mutant activates Ral through interaction with RalGEFs, which contain the Ras association domain. However, little is known with regard to the mechanism that governs aberrant activation of Ral in bladder cancer, in which Ras mutations are relatively infrequent. Here, we show that Ral was highly activated in invasive bladder cancer cells due to reduced expression of RalGAPα2, the dominant catalytic subunit in bladder, rather than increased expression of RalGEFs. Exogenous expression of wild-type RalGAPα2 in KU7 bladder cancer cells with invasive phenotype, but not mutant RalGAPα2-N1742K lacking RalGAP activity, resulted in attenuated cell migration in vitro and lung metastasis in vivo. Furthermore, genetic ablation of Ralgapa2 promoted tumor invasion in a chemically-induced murine bladder cancer model. Importantly, immunohistochemical analysis of human bladder cancer specimens revealed that lower expression of RalGAPα2 was associated with advanced clinical stage and poor survival of patients. Collectively, these results are highly indicative that attenuated expression of RalGAPα2 leads to disease progression of bladder cancer through enhancement of Ral activity.


  • Open Access

    Effects of PPIs and an H2 blocker on the Antiplatelet Function of Clopidogrel in Japanese Patients under Dual Antiplatelet Therapy

    by Keiichiro Yamane, Yoshihiro Kato, Junichi Tazaki, Tomohisa Tada, Takeru Makiyama, Masao Imai, Toshikazu Jinnai, Tomoyuki Ikeda, Ryutaro Shirakawa, Takeshi Kimura, et al.

    Aim: Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is essential after percutaneous coronary intervention (PCI). Clopidogrel is a prodrug and changed into active metabolite by cytochrome p450 enzymes (CYPs), especially CYP2C19. Proton pump inhibitors (PPIs) are used for the prevention of aspirin-induced gastrointestinal bleeding. PPIs are also metabolized by CYP2C19, although the degree of its contribution is dependent on the kind of PPI. Omeprazole, a PPI, has been reported to weaken the antiplatelet effects of clopidogrel. Famotidine, a histamine receptor type 2 (H2) blocker, could also be an alternative to PPIs. The aim of this study was to evaluate the effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel. Methods: Patients receiving DAPT due to prior PCI, who took either omeprazole or rabeprazole, were enrolled (n=25). The initial PPI was changed to the other PPI as a crossover study. In another study, patients undergoing DAPT without taking PPIs or H2 blockers were enrolled (n=30) and famotidine was added. Results: Platelet aggregability when taking omeprazole was higher than when taking rabeprazole, evaluated by an optical aggregometer using collagen as a stimulus (p=0.0051) and by the VerifyNow P2Y12 assay (p=0.0060). Platelet aggregability when taking rabeprazole was comparable to that in control patients (n=15). Concomitant use of famotidine had no effect. Conclusion: Omeprazole significantly reduced the antiplatelet effect of clopidogrel and this effect on clopidogrel was stronger than that of rabeprazole. Concomitant use of famotidine had no effect on the antiplatelet effect of clopidogrel.


  • Open Access

    Proton-Pump Inhibitors Could Be Innocent When Used Concomitantly With Clopidogrel

    by Hisanori Horiuchi

    Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies


  • Open Access

    Flightless-I (Fli-I) Regulates the Actin Assembly Activity of Diaphanous-related Formins (DRFs) Daam1 and mDia1 in Cooperation with Active Rho GTPase

    by Tomohito Higashi, Tomoyuki Ikeda, Takaaki Murakami, Ryutaro Shirakawa, Mitsunori Kawato, Katsuya Okawa, Mikio Furuse, Takeshi Kimura, Toru Kita, Hisanori Horiuchi


  • ASPIRIN EFFICACY: ANALYSIS OF WHOLE BLOOD-AGGREGATION USING THE SCREEN FILTRATION PRESSURE METHOD

    by H. Kondo, A. Tabuchi, R. Taniguchi, M. Kawato, T. Ikeda, T. Morimoto, T. Kita, H. Horiuchi

  • Open Access

    Compensated endocytosis of LDL by hamster cells co-expressing the two distinct mutant LDL receptors defective in endocytosis and ligand binding

    by Hiroyuki Yoshida, Masayuki Yokode, Akitsugu Yamamoto, Ryuichi Masaki, Toshinori Murayama, Hisanori Horiuchi, Toru Kita


    • 1 December 1998
      • Vol. 80  (6) , 1032-3

    Steroid hormone-responsive secondary factor X deficiency.

    by A Hamasaki, K Ishii, K Yamaguchi, M Sunamoto, H Ozaki, M Yanagita, Y Wakatsuki, H Horiuchi, Y Nakahata, T Kita